SLC6A3 and Parkinson disease: The remainder of this review will consider each of the three main classes of MAUIs, that is, SERT, DAT, and NET inhibitors, and will describe their effect on motor and nonmotor symptoms of PD and treatment-related complications, either as monotherapy or as adjuncts to L-DOPA.